Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                News & Events for Human Drugs

News & Events for Human Drugs

                        CDER Conversations
          Q&A with FDA
          Spotlight on CDER Science


                        From Our Perspective Home
          Drugs
          News & Events for Human Drugs
          FDA approves drug combination treatment for adults with asthmaNews & Events for Human Drugs FDA approves drug combination treatment for adults with asthma
  
  	
    Share
    Post
    Linkedin

    Email
    PrintAction

FDA has approved Airsupra (albuterol and budesonide) inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients with asthma 18 years of age and older. Airsupra is a combination of albuterol (a beta-2 adrenergic agonist) and budesonide (a corticosteroid). It is the first combination of an inhaled corticosteroid (ICS) and a short-acting beta-agonist to be approved in the U.S. Additionally, Airsupra is the first product containing an ICS to be approved in the U.S. as a reliever treatment (rather than as a controller) for asthma. The treatment works to relax the muscles and reduce inflammation in the lung airways to reduce the risk of severe asthma attacks. Airsupra is given as two oral inhalations of a combination of albuterol 90 mcg and budesonide 80 mcg per inhalation (total dose albuterol 180 mcg and budesonide 160 mcg) as needed for asthma symptoms.

Disease or Condition

Asthma is a long-term condition that causes the airways to become inflamed and narrow. Symptoms of an asthma attack include coughing, periods of wheezing, chest tightness, and shortness of breath. More than 24 million people in the U.S. have asthma. Asthma symptoms can vary from person to person and severity of symptoms can change over time.

Effectiveness

The efficacy of Airsupra to reduce the risk of severe asthma attacks was evaluated in patients with moderate to severe asthma in MANDALA (NCT03769090), a randomized, double-blind, multicenter study. Patients were randomized to Airsupra 180 mcg/ 160 mcg or albuterol 180 mcg and instructed to take as needed for asthma symptoms. MANDALA was a variable length exacerbation study during which patients received treatment for at least 24 weeks.

The primary efficacy endpoint was the time to first severe asthma attack (defined as worsening or onset of asthma symptoms that required systemic corticosteroids for at least three days or an emergency room visit that led to the use of systemic corticosteroids for at least three days or a hospitalization for at least 24 hours due to asthma).

In adult patients, treatment with Airsupra, compared with albuterol, demonstrated a 28% reduction in the risk of a severe asthma attack as assessed by the time to first severe asthma attack.

Safety Information

The most common side effects of Airsupra are headache, oral candidiasis, cough, and difficulty speaking. Patients with hypersensitivity to albuterol, budesonide, or to any of the additional ingredients should avoid Airsupra. Patients should take no more than six doses (12 inhalations) in a 24-hour period. Patients with cardiovascular disorders, convulsive disorders, hyperthyroidism, diabetes mellitus, and ketoacidosis effects should use with caution.

See full prescribing information for additional information on risks associated with Airsupra.

Designations

Airsupra received standard review for this indication.

                                                                                  Content current as of:
      01/11/2023
              
              
Regulated Product(s)
		 DrugsNews & Events for Human Drugs

          
                        CDER Conversations
          Q&A with FDA
          Spotlight on CDER Science


                        From Our Perspective
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop